Alk-Abello ASWBO:ALKB -0.12%65 PEG Ratio is 1.15 as of Jun. 26, 2026, which is 23% below its 10-year median of 1.50. GuruFocus rates WBO:ALKB with a GF Score™ of 65/100 and a GF Value™ of €27.26 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 95 Biotechnology companies, Alk-Abello AS ranks better than 64.21% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Alk-Abello AS's PEG Ratio or its related term are showing as below:
WBO:ALKB'
s PEG Ratio Range Over the Past 10 Years
Min: 0.87 Med: 1.5 Max: 28.17
Current: 1.16
During the past 13 years, Alk-Abello AS's highest PEG Ratio was 28.17. The lowest was 0.87. And the median was 1.50.
WBO:ALKB's PEG Ratio is ranked better than 64.21% of 95
companies
in the Biotechnology industry
Industry Median: 1.92
vs WBO:ALKB: 1.16
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Alk-Abello AS (WBO:ALKB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Alk-Abello AS PEG Ratio Related Terms
Alk-Abello AS PEG Ratio Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ALKB vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Alk-Abello AS's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Alk-Abello AS (WBO:ALKB) has a PEG Ratio of 1.15 as of Jun. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Alk-Abello AS and its competitors. This is 23% below median its historical median of 1.50. Over the past decade, Alk-Abello AS's PEG Ratio has ranged from 0.87 to 28.17. According to the industry distribution chart, Alk-Abello AS ranks #34 out of 95 companies in the Biotechnology industry, placing it in the top 35.8%.
Is Alk-Abello AS's PEG Ratio too high?
Alk-Abello AS's current PEG Ratio of 1.15 is 23% below median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 28.17. The Biotechnology industry median PEG Ratio is 1.92. Alk-Abello AS's value of 1.15 is 40.1% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #34 out of 95 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #34 out of 95 companies for PEG Ratio. This puts Alk-Abello AS in the upper half of its industry. The industry median PEG Ratio is 1.92. Alk-Abello AS's value of 1.15 is 40.1% below this benchmark. Historically, Alk-Abello AS's own PEG Ratio has ranged from 0.87 to 28.17 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 1.92, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.92, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current PEG Ratio of 1.15 is 40.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current PEG Ratio is 1.15, which is 23% below median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.26, compared to a current price of €34.22 — trading 25.5% above its estimated fair value. The current PEG Ratio is 1.15, which is 23% below median its 10-year median of 1.50 and 40.1% below the Biotechnology industry median of 1.92. Alk-Abello AS's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current PEG Ratio is 1.15 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for WBO:ALKB:
PEG Ratio: 1.15 (23% below median its 10-year median of 1.50)
GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
Industry Position: 40.1% below the Biotechnology median (#34 of 95)
No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
65GF Score
Get the complete analysis for WBO:ALKB
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALKB has been successfully added to your 
